Guardian Pharmacy Services, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-68.2% vs price
Base Case (Median)
-39.7% vs price
Bull Case (75th pct.)
-31.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $26.46 | -30.4% | High (40%) |
| PE Comparable | $22.92 | -39.7% | Medium (25%) |
| Growth Trajectory DCF | $26.44 | -30.4% | Medium (20%) |
| Graham Number | $8.74 | -77.0% | Medium (40%) |
| EV/EBITDA | $15.46 | -59.3% | Medium (20%) |
| EV/FCF | $25.58 | -32.7% | Medium (20%) |
| Earnings Power Value | $4.56 | -88.0% | Medium (50%) |
Based on 7 out of 8 methods, GRDN appears overvalued at the current price of $38.00. The base case fair value of $22.92 implies 39.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.